Araris Biotech AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Araris Biotech AG
In Vivo’s 2023 Rising Leaders: Healthcare Innovators At The Top Of Their Game
The fourth annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in healthcare.
Deal Watch: Japan’s SNBL To Re-Absorb US Spinout Satsuma
Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.
Finance Watch: Biopharma VC Funding Dips In Q3, Remains Relatively High For Year
Private Company Edition: Third quarter venture capital funding for biopharmaceutical firms fell from Q2, but activity remains near all-time highs year-to-date. Several companies announced VC financings in early October, including Ascidian, which launched with $50m in series A financing.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
- Chiral Chemistry
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
- Synthesis Technologies, Production Processes
Drug Discovery Tools
- Molecular Diversity
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.